Pelotonia awards six grants to Ohio State

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

PELOTONIA awarded six, two-year grants to projects at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute.

Pelotonia is a fundraising bicycle tour established in 2009 to raise money for cancer research at Ohio State. In the past four years, 67 OSUCCC – James research teams have received Pelotonia Idea Grants. A total of $650,000 will be awarded in this latest round of grants, with $6.6 million in funding awarded since the program’s inception.

The 2014 Pelotonia Idea Grants funded the following projects: Identifying and Developing New Immunoagents for Cancer Diagnosis and Therapy; Proteasomal Pathway Regulates PTEN Protein Degradation and Promotes Carcinogenesis; A Mass-Spectrometry Approach to Mapping Histone Modification Crosstalk; Develop IL-27 Based Combinational Immunotherapy of Cancer; Ceragenin-based Therapy for Multiple Myeloma; and Defining the Role of Autophagy in Anoikis Resistance and in Peritoneal Carcinomatosis/Sarcomatosis.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login